Search Browse Earnings

Oncotelic Therapeutics, Inc. — SlamSEC

Oncotelic Therapeutics, Inc.

OTC:OTLC

Pharmaceutical Preparations·AGUORA HILLS, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$1.7M

+0.0% YoY

FY 2021

Adj. EBITDA

-$6.6M

-381.3% margin

FY 2024

Net Income

-$7.9M

-454.0% margin

FY 2024

EPS (Diluted)

$0.01

FY 2023

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$241,452

FY 2023

Total Debt

$1.8M

FY 2024

Net Debt

$1.5M

FY 2024

Enterprise Value

—

Debt / EBITDA

-0.2x

FY 2021

EV / EBITDA

—

Employees

—

CEO

Trieu Vuong